Ursodeoxycholic Acid Market Share| Industry Analysis| Current Trends| Market Forecast (2019-2026)-DataM Intelligence
The Global Ursodeoxycholic acid market was worth XX million in 2018 and is forecasted to reach 819.61 million by 2026, growing at a CAGR of 10% during the forecast period (2019-2026).
(EMAILWIRE.COM, November 14, 2019 ) Market Overview:-
Ursodeoxycholic acid (UDCA) is a naturally occurring bile used to dissolve gallstones that are rich in cholesterol and cholestatic liver disease. The acid is also used to enhance the flow of bile in primary biliary cirrhosis and cystic fibrosis.
The market for ursodeoxycholic acid is moderately competitive, with the development of end-products and elimination of end-products still at a nascent stage.
Market Dynamics:-
• The rise in cases of gallstone problems and cholestatic liver diseases have increased the demand for ursodeoxycholic acid end-products.
• According to the 2017 Annual Data Report published by the Cystic Fibrosis Foundation, 12.8 percent of individuals are prescribed ursodeoxycholic acid, which is most commonly prescribed to those with abnormal liver function tests or suspected CF liver disease.
• The occurrence of gallstones in women and older adults have driven the demand for ursodeoxycholic acid, as the ursodeoxycholic acid can dissolve the smaller stones made primarily of cholesterol. Ursodeoxycholic acid also reduces the absorption of cholesterol from the intestinal tract.
• The side effects occurring in patients, including diarrhea, indigestion, headache, and nausea or vomiting might hamper the growth of the market.
• A recent study published by the National Center for Biotechnology Information (NCBI) showed the occurrence of diarrhea in patients prescribed with UDCA in the range of 3-7%. The other side-effects such as back pain, fever, cough, and hair loss might also act as market deterrents
Market Segmentation:-
The ursodeoxycholic acid market is segmented by type into:
• Synthetic USDA
• Extraction USDA
The Synthetic USDA end-products are expected to dominate the market share during the forecast period, with the segment value at 317 USD million in 2017.
The synthetic acid is widely used in the treatment of gallstones and is marketed under multiple trade names such as Actibile, Actigall, Ursolic, Ursofalk, and Steiner. For instance, in May 2016, the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA.
By application, the market is categorized into:
• Pharmacy
• Health products
The end products are most widely used in health products, with the segment dominating the market share in 2017 at 299 USD million.
The end-products in health products come in the form of tablets and capsules which are marketed by pharmaceutical companies as alternatives to the surgical procedure of gallstones operation.
Download free report sample (For Region specific data) @https://www.datamintelligence.com/download-sample/ursodeoxycholic-acid-market
Geographical Trends:-
Global market is divided into:
• North America
• Europe
• South America
• Asia-Pacific
• The Middle East and Africa
The Asia-Pacific region is the leading geographical segment by market revenue owing to the rise in production and product sales of the end-products in leading countries such as China and Japan.
The number of patients and prevalence of primary biliary cholangitis, the chronic cholestatic liver disease is increasing in China, with the majority of patients treated with ursodeoxycholic acid medical therapy, thus driving demand for the UDCA market in the region.
Competitive Landscape:-
The key players of the market include:
• Abil Chempharma Private Limited
• AS Grindeks
• Biotavia Labs Pvt Ltd.
• Mitsubishi Tanabe Pharma Corporation
• ICE
The companies focus on the expansion of product portfolio and business reach through mergers and acquisitions.
Key Takeaways:
• In June 2016, Retrophin, Inc. announced the signing of a definitive agreement to purchase the rights, titles, and ownership of a liquid formulation of ursodeoxycholic acid from Asklepion Pharmaceuticals, LLC.
• The synthetic UDCA market segment is expected to continue its domination by market share during the forecast period owing to the development and innovation of the synthesis techniques involved in the manufacturing of synthetic UDCA.
• Asia-Pacific is the leading geographical segment due to the rise in production and product sales of the end-products in leading countries such as China and Japan.
• The companies are focused on the launch of new products to strengthen market position and increase company revenue. For instance in May 2015, AS Grindeks announced the introduction of the final dosage form (capsule) of Ursodeoxycholic acid (UDCA) and started its export to Russia and Georgia.
View full report sample @https://www.datamintelligence.com/research-report/ursodeoxycholic-acid-market
For any queries/customization about the report@https://www.datamintelligence.com/enquiry/ursodeoxycholic-acid-market
About Us:
DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision-making in designing disruptive solutions. We monitor and analyze the market by dissecting various parameters such as market influencers, competitive intensity, innovations, trends, and emerging products.
For more information:
Sai Kiran
Sales Manager
Website: www.datamintelligence.com
E-mail: pr@datamintelligence.com
Ursodeoxycholic acid (UDCA) is a naturally occurring bile used to dissolve gallstones that are rich in cholesterol and cholestatic liver disease. The acid is also used to enhance the flow of bile in primary biliary cirrhosis and cystic fibrosis.
The market for ursodeoxycholic acid is moderately competitive, with the development of end-products and elimination of end-products still at a nascent stage.
Market Dynamics:-
• The rise in cases of gallstone problems and cholestatic liver diseases have increased the demand for ursodeoxycholic acid end-products.
• According to the 2017 Annual Data Report published by the Cystic Fibrosis Foundation, 12.8 percent of individuals are prescribed ursodeoxycholic acid, which is most commonly prescribed to those with abnormal liver function tests or suspected CF liver disease.
• The occurrence of gallstones in women and older adults have driven the demand for ursodeoxycholic acid, as the ursodeoxycholic acid can dissolve the smaller stones made primarily of cholesterol. Ursodeoxycholic acid also reduces the absorption of cholesterol from the intestinal tract.
• The side effects occurring in patients, including diarrhea, indigestion, headache, and nausea or vomiting might hamper the growth of the market.
• A recent study published by the National Center for Biotechnology Information (NCBI) showed the occurrence of diarrhea in patients prescribed with UDCA in the range of 3-7%. The other side-effects such as back pain, fever, cough, and hair loss might also act as market deterrents
Market Segmentation:-
The ursodeoxycholic acid market is segmented by type into:
• Synthetic USDA
• Extraction USDA
The Synthetic USDA end-products are expected to dominate the market share during the forecast period, with the segment value at 317 USD million in 2017.
The synthetic acid is widely used in the treatment of gallstones and is marketed under multiple trade names such as Actibile, Actigall, Ursolic, Ursofalk, and Steiner. For instance, in May 2016, the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA.
By application, the market is categorized into:
• Pharmacy
• Health products
The end products are most widely used in health products, with the segment dominating the market share in 2017 at 299 USD million.
The end-products in health products come in the form of tablets and capsules which are marketed by pharmaceutical companies as alternatives to the surgical procedure of gallstones operation.
Download free report sample (For Region specific data) @https://www.datamintelligence.com/download-sample/ursodeoxycholic-acid-market
Geographical Trends:-
Global market is divided into:
• North America
• Europe
• South America
• Asia-Pacific
• The Middle East and Africa
The Asia-Pacific region is the leading geographical segment by market revenue owing to the rise in production and product sales of the end-products in leading countries such as China and Japan.
The number of patients and prevalence of primary biliary cholangitis, the chronic cholestatic liver disease is increasing in China, with the majority of patients treated with ursodeoxycholic acid medical therapy, thus driving demand for the UDCA market in the region.
Competitive Landscape:-
The key players of the market include:
• Abil Chempharma Private Limited
• AS Grindeks
• Biotavia Labs Pvt Ltd.
• Mitsubishi Tanabe Pharma Corporation
• ICE
The companies focus on the expansion of product portfolio and business reach through mergers and acquisitions.
Key Takeaways:
• In June 2016, Retrophin, Inc. announced the signing of a definitive agreement to purchase the rights, titles, and ownership of a liquid formulation of ursodeoxycholic acid from Asklepion Pharmaceuticals, LLC.
• The synthetic UDCA market segment is expected to continue its domination by market share during the forecast period owing to the development and innovation of the synthesis techniques involved in the manufacturing of synthetic UDCA.
• Asia-Pacific is the leading geographical segment due to the rise in production and product sales of the end-products in leading countries such as China and Japan.
• The companies are focused on the launch of new products to strengthen market position and increase company revenue. For instance in May 2015, AS Grindeks announced the introduction of the final dosage form (capsule) of Ursodeoxycholic acid (UDCA) and started its export to Russia and Georgia.
View full report sample @https://www.datamintelligence.com/research-report/ursodeoxycholic-acid-market
For any queries/customization about the report@https://www.datamintelligence.com/enquiry/ursodeoxycholic-acid-market
About Us:
DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision-making in designing disruptive solutions. We monitor and analyze the market by dissecting various parameters such as market influencers, competitive intensity, innovations, trends, and emerging products.
For more information:
Sai Kiran
Sales Manager
Website: www.datamintelligence.com
E-mail: pr@datamintelligence.com
Contact Information:
DataM Intelligence
Sai
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results